Expanded access policy

Vaderis Therapeutics AG (“Vaderis”) is a clinical-stage pharmaceutical company committed to developing effective interventions for HHT to improve patients’ lives. Vaderis is committed to developing innovative therapies and making them available to patients through clinical trials and regulatory approval. Expanded access, also referred to as compassionate use, is a regulatory mechanism by which an investigational drug can be made available outside of a clinical trial to treat patients with serious or life-threatening conditions for which there are no satisfactory treatment options.

We currently do not offer engasertib through an expanded access program, as we consider participation in our clinical trials to be the most appropriate means of access. Please visit https://clinicaltrials.gov and https://euclinicaltrials.eu/ for more information about current Vaderis clinical trials.

We will continue to evaluate the possibility of expanded access as we advance development of our investigational medicines and may revise this expanded access policy at any time. The availability of this policy or any revised version shall not serve as a guarantee of access to engasertib or any other investigational medicines by any individual patient. If you have additional questions, please contact clindev@vaderis.com.